Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2025-07-08 Regulatory Filings
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Regulatory Filings Classification · 95% confidence The document is a press release announcing Biophytis's participation in a scientific conference (ARC 2025) and the upcoming presentation of clinical data. It does not contain financial results, regulatory filings, or specific corporate actions like dividends or share changes. As it is a general corporate announcement that does not fit into the specific categories provided, it falls under the fallback category of Regulatory Filings (RNS).
2025-07-08 English
Obésité : Biophytis Trace sa Voie vers un Marché en Pleine Explosion
Regulatory Filings Classification · 95% confidence The document is a press release from Biophytis SA regarding their strategic positioning and market potential for their drug candidate BIO101 in the obesity market. It discusses business strategy, market outlook, and clinical development plans rather than reporting specific quarterly financial results, audit findings, or regulatory filings. As it is a general corporate announcement regarding business operations and strategy that does not fit into more specific categories like earnings releases or M&A, it is classified as a general regulatory announcement (RNS).
2025-07-07 French
Obesity: Biophytis Charts Its Course Toward a Booming Market
Earnings Release Classification · 95% confidence The document is a press release issued by Biophytis regarding their strategic positioning and market potential for their drug candidate BIO101 in the obesity market. It does not contain financial statements, audit results, or specific regulatory filings, but rather serves as a corporate communication to investors and the public about business strategy and clinical development. As it does not fit into specific categories like 10-K, ER, or CT, and is a general corporate announcement, it falls under the Regulatory Filings (RNS) category as a catch-all for miscellaneous corporate announcements. FY 2023
2025-07-07 English
Biophytis Propulse l’Innovation dans l’Obésité, la Santé Musculaire et la Longévité à la BIO International 2025
Regulatory Filings Classification · 95% confidence The document is a press release issued by Biophytis regarding their participation in the BIO International 2025 convention. It summarizes the company's activities, research progress in obesity and sarcopenia, and post-conference momentum. It does not constitute a formal financial report, audit, or regulatory filing, but rather a corporate communication/announcement of business activities. As it does not fit into specific categories like earnings releases or board changes, it falls under the general regulatory announcement category.
2025-07-03 French
Information sur les comptes annuels
Report Publication Announcement Classification · 100% confidence The document is a short press release (3,640 characters) from Biophytis announcing a delay in the publication of their 2024 annual financial statements. It does not contain the financial statements themselves, but rather serves as an official notification regarding the timing of a future report release. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-06-30 French
Information on the Annual Financial Statements
Report Publication Announcement Classification · 100% confidence The document is a short press release (under 5,000 characters) from Biophytis announcing a delay in the publication of their 2024 annual accounts. It does not contain the financial statements themselves, but rather serves as an announcement regarding the timing of a report's release. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-06-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.